2025年1月10日
RADNOR, PA. – 2025年1月10日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the appointment of Tiffany Woodworth as Head of Biometrics, Data Science and Access. This strategic appointment underlines Certara’s commitment to advancing its capabilities in modeling and simulation, regulatory science, and market access. In this role, she will lead the biostatistics, statistical programming, PK/PD programming, advanced analytics, data science, market access and real-world evidence teams at Certara.
Ms. Woodworth has 19 years of leadership experience in the Life Sciences industry, successfully steering teams through strategic growth and operational excellence. She joins Certara from Panalgo, where she served as President and General Manager, delivering significant revenue growth and profitability. She received her MPH at Boston University School of Public Health and her MBA from the Fox School of Business at Temple University.
“Certara’s mission to accelerate medicines to patients through innovation aligns perfectly with my own career principles, as does the talented team of colleagues I’ll be working alongside,” said Tiffany Woodworth. “I’m excited to lead the Biometrics, Data Science and Access team and further expand our ability to deliver cutting-edge solutions that improve global healthcare.”
Patrick Smith, President, Certara Drug Development Solutions, commented, “Tiffany’s leadership and proven track record in biometrics and data science make her a valuable asset to our team. We are enthusiastic about the role she’ll play in helping us deliver solutions that help our clients develop safer, more effective medicines, faster.”
Certara（サターラ）について
サターラは、モデリング＆シミュレーション・ソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。製薬、教育機関、規制当局のお客様 2,400人以上、66ヵ国にてサターラの技術やサービスが活用されています。Learn more at www.certara.com.
